NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models

Journal: Science Translational Medicine

Published: 2021-02-03

DOI: 10.1126/scitranslmed.abb2181

Affiliations: 7

Authors: 39

Go to article
Institutions Share
Novartis Institute for Tropical Diseases (NITD), Singapore 0.54
Novartis Institutes for Biomedical Research (NIBR), United States of America (USA) 0.41
Novartis Singapore Pte Ltd., Singapore 0.03
Utah State University (USU), United States of America (USA) 0.03